Literature DB >> 721317

Immunotherapy with an intralesionally administered synthetic cord factor analogue.

E Yarkoni, H J Rapp, J Polonsky, E Lederer.   

Abstract

Injection of emulsified 6,6'-di-O-2-tetradecyl-3-hydroxyoctadecanoyl-a, a trehalose designated C76, a synthetic analogue of the mycobacterial glycolipid trehalose-6,6'-dimycolate (TDM), into transplants of an established, syngeneic murine fibrosarcoma induced complete regression of tumor in a number of animals. The number of animals in which tumor regressed completely dependent on the amount of oil in the emulsion. On a weight basis, C76 was at least as active as TDM. Intralesional injection of an emulsified mixture of C76 and endotoxin (ET) or of TDM and ET caused regression of an established transplant of a guinea-pig hepatoma in syngeneic animals. In mice, intravenously administered emulsions of C76 were less toxic and less granulomagenic than those made with TDM.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 721317     DOI: 10.1002/ijc.2910220510

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Influence of oil and Tween concentrations on enhanced endotoxin lethality in mice pretreated with emulsified trehalose-6,6'-dimycolate (cord factor).

Authors:  E Yarkoni; H J Rapp
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

2.  Effect of sulfolipid I on trehalose-6,6'-dimycolate (cord factor) toxicity and antitumor activity.

Authors:  E Yarkoni; M B Goren; H J Rapp
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

3.  Regression of a murine fibrosarcoma after intralesional injection of a synthetic C39 glycolipid related to cord factor.

Authors:  E Yarkoni; H J Rapp; J Polonsky; J Varenne; E Lederer
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

Review 4.  Muramyl peptides. Chemical structure, biological activity and mechanism of action.

Authors:  A Adam; J F Petit; P Lefrancier; E Lederer
Journal:  Mol Cell Biochem       Date:  1981-12-04       Impact factor: 3.396

5.  Three types of mycolic acid from Mycobacterium tuberculosis Brévanne: implications for structure-function relationships in pathogenesis.

Authors:  R Toubiana; J Berlan; H Sato; M Strain
Journal:  J Bacteriol       Date:  1979-07       Impact factor: 3.490

6.  Regression of a transplanted guinea pig hepatoma after intralesional injection of an emulsified mixture of endotoxin and mycobacterial sulfolipid.

Authors:  E Yarkoni; M B Goren; H J Rapp
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

7.  Growth inhibition of tumour cells by a liposome-encapsulated, mycolic acid-containing glycolipid, trehalose 2,3,6'-trimycolate.

Authors:  Y Ohtsubo; M Furukawa; T Imagawa; N Sugimoto; M Ikutoh; S Nakatsugi; Y Katoh; S Shinka; Y Dohi
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

8.  Parallel antitumor, granuloma-forming and tumor-necrosis-factor-priming activities of mycoloyl glycolipids from Nocardia rubra that differ in carbohydrate moiety: structure-activity relationships.

Authors:  Y Natsuhara; S Oka; K Kaneda; Y Kato; I Yano
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 9.  Identification and Biological Activity of Synthetic Macrophage Inducible C-Type Lectin Ligands.

Authors:  Chriselle D Braganza; Thomas Teunissen; Mattie S M Timmer; Bridget L Stocker
Journal:  Front Immunol       Date:  2018-01-17       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.